{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2239.5","upperLimit":"2983.8","value":"2585.0"}]}],"title":"Anti-HPV Type 6 (n=109)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2191.4","upperLimit":"2964.3","value":"2548.7"}]}],"title":"Anti-HPV Type 11 (n=109)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9605.6","upperLimit":"12378.7","value":"10904.3"}]}],"title":"Anti-HPV Type 16 (n=123)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2531.1","upperLimit":"3340.7","value":"2907.9"}]}],"title":"Anti-HPV Type 18 (n=137)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1538.8","upperLimit":"1979.8","value":"1745.4"}]}],"title":"Anti-HPV Type 31 (n=130)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1848.7","upperLimit":"2373.9","value":"2094.9"}]}],"title":"Anti-HPV Type 33 (n=136)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"386.9","upperLimit":"500.4","value":"440.0"}]}],"title":"Anti-HPV Type 45 (n=143)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"991.6","upperLimit":"1291.1","value":"1131.5"}]}],"title":"Anti-HPV Type 52 (n=129)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1803.1","upperLimit":"2273.2","value":"2024.6"}]}],"title":"Anti-HPV Type 58 (n=127)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"150"}],"units":"Participants"}],"description":"Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL. This outcome measure applied to Cohort 1 participants only.","dispersionType":"95% Confidence Interval","groups":[{"description":"V503 mid-dose 0.5 mL injection in a 3-dose regimen in the Base Study. A subset of participants (Cohort 1) received a fourth V503 mid-dose vaccination in the extension study.","id":"OG000","title":"Extension Study: Mid-dose V503 (Cohort 1)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants in Cohort 1 who received all 3 vaccinations of mid-dose V503 in the Base Study, were seronegative at Day 1 and PCR negative from Day 1 to Month 7 for the relevant HPV types, had no other violation that could interfere with evaluation of immune response, and provided post-dose 4 serum.","reportingStatus":"POSTED","timeFrame":"Month 61: 28 days postdose 4 in the Extension Study (Cohort 1)","title":"Extension Study: Geometric Mean Titers to HPV Types 6/11/16/18/31/33/45/52/58 at Day 28 Postdose 4","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"milli Merck U/mL"}